期刊
FUTURE ONCOLOGY
卷 18, 期 14, 页码 1757-1775出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-0862
关键词
CTLA-4; EGFR-TKIs; EGFR mutations; immunotherapy; non-small-cell lung cancer; PD-1; PD-L1; resistance; tumor microenvironment
类别
资金
- National Natural Science Youth Foundation of China [81501971]
- China Postdoctoral Science Foundation [2018M630603]
- Natural Science Youth Foundation of Jiangsu Province [BK20150252]
- Human Resource Summit Grant of Jiangsu Province [WSW142]
- Youth Medical Professionals Foundation of Jiangsu Province [QNRC2016279]
The rapid development of molecular targeted therapy brings hope to patients with advanced non-small-cell lung cancer. However, drug resistance occurs during EGFR-TKI treatment. Osimertinib shows a favorable prognosis, but acquired resistance is still a challenge. PD-1 and PD-L1 inhibitors have made progress, especially in patients with no actionable mutations. This review summarizes the relationship between EGFR mutations and PD-L1 expression and important clinical studies on immunotherapy-inhibitor-based treatment in EGFR-TKI-resistant NSCLC patients.
The rapid development of molecular targeted therapy brings hope to patients with advanced non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during treatment with EGFR-tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation EGFR-TKI, shows a favorable prognosis in T790M-positive NSCLC. Unfortunately, acquired resistance is still a challenge for both patients and clinicians. There is still no consensus on the optimal treatment. PD-1 and its ligand receptor 1 (PD-L1) inhibitors have yielded great progress, especially in patients with no actionable mutations. In this review, the authors take stock of the relationship between EGFR mutations and PD-L1 expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC. Plain language summary Lung cancer is one of the most common malignant cancers worldwide. Specific genes are known to drive cancer growth in advanced non-small-cell lung cancer (NSCLC) and targeted therapies against these genes and their proteins have significantly improved survival. However, resistance to these therapies inevitably occurs and there is still no consensus on the best treatment strategy after resistance develops. Several related articles have discussed the relationship between treatment resistance and the production of PD-L1 proteins in cancer cells (which helps them avoid the body's immune system). EGFR-tyrosine kinase inhibitors (TKIs), a type of targeted therapy, were also reported to influence the production of PD-L1. Therefore, the authors hypothesize that immunotherapy (a type of targeted therapy that forces the body's immune system to attack cancers regardless of PD-L1 production) may be a new option for treatment-resistant patients. In this review, the feasibility of EGFR-TKIs in combination with immunotherapy is clarified.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据